Kinnari Pandya
PKC? attenuates jagged-1-mediated notch signaling in ErbB-2-positive breast cancer to reverse trastuzumab resistance
Pandya, Kinnari; Wyatt, Debra; Gallagher, Brian; Shah, Deep; Baker, Andrew; Bloodworth, Jeffrey; Zlobin, Andrei; Pannuti, Antonio; Green, Andrew; Ellis, Ian O.; Filipovic, Aleksandra; Sagert, Jason; Rana, Ajay; Albain, Kathy S.; Miele, Lucio; Denning, Mitchell F.; Osipo, Clodia
Authors
Debra Wyatt
Brian Gallagher
Deep Shah
Andrew Baker
Jeffrey Bloodworth
Andrei Zlobin
Antonio Pannuti
ANDREW GREEN ANDREW.GREEN@NOTTINGHAM.AC.UK
Associate Professor
Ian O. Ellis
Aleksandra Filipovic
Jason Sagert
Ajay Rana
Kathy S. Albain
Lucio Miele
Mitchell F. Denning
Clodia Osipo
Abstract
Purpose: Breast cancer is the second leading cause of cancer mortality among women worldwide. The major problem with current treatments is tumor resistance, recurrence, and disease progression. ErbB-2–positive breast tumors are aggressive and frequently become resistant to trastuzumab or lapatinib. We showed previously that Notch-1 is required for trastuzumab resistance in ErbB-2–positive breast cancer.
Experimental Design: Here, we sought to elucidate mechanisms by which ErbB-2 attenuates Notch signaling and how this is reversed by trastuzumab or lapatinib.
Results: The current study elucidates a novel Notch inhibitory mechanism by which PKCα downstream of ErbB-2 (i) restricts the availability of Jagged-1 at the cell surface to transactivate Notch, (ii) restricts the critical interaction between Jagged-1 and Mindbomb-1, an E3 ligase that is required for Jagged-1 ubiquitinylation and subsequent Notch activation, (iii) reverses trastuzumab resistance in vivo, and (iv) predicts better outcome in women with ErbB-2–positive breast cancer.
Conclusions: The clinical impact of these studies is PKCα is potentially a good prognostic marker for low Notch activity and increased trastuzumab sensitivity in ErbB-2–positive breast cancer. Moreover, women with ErbB-2–positive breast tumors expressing high Notch activation and low PKCα expression could be the best candidates for anti-Notch therapy.
Journal Article Type | Article |
---|---|
Acceptance Date | Aug 25, 2015 |
Online Publication Date | Sep 8, 2015 |
Publication Date | 2016-01 |
Deposit Date | Apr 24, 2018 |
Print ISSN | 1078-0432 |
Publisher | American Association for Cancer Research |
Peer Reviewed | Peer Reviewed |
Volume | 22 |
Issue | 1 |
Pages | 175-186 |
DOI | https://doi.org/10.1158/1078-0432.CCR-15-0179 |
Public URL | https://nottingham-repository.worktribe.com/output/1118165 |
Publisher URL | http://clincancerres.aacrjournals.org/content/22/1/175 |
PMID | 26350262 |
You might also like
Cell Division Cycle 6 (CDC6) is an Independent Prognostic Biomarker in Breast Cancer
(2024)
Journal Article
The role of the ALKBH5 RNA demethylase in invasive breast cancer
(2024)
Journal Article
Stromal lymphocytes are associated with upgrade of B3 breast lesions
(2024)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search